@ARTICLE{
author={Cho Byoung Chul,...,Zaric Bojan},
year={2023},
title={Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={41},
number={26},
pages={4208-+},
document_type={Article},
} 

@ARTICLE{
author={Cho Byoung Chul,...,Zaric Bojan},
year={2022},
title={A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)},
journal={ANNALS OF ONCOLOGY},
volume={38},
number={9},
pages={S1560-S1560},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Cho Byoung Chul,...,Secen Nevena M,...,(broj koautora 19)},
year={2022},
title={Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study},
journal={LANCET ONCOLOGY},
volume={23},
number={6},
pages={781-792},
document_type={Article},
}